These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 8537682)

  • 41. MN and IIIB recombinant glycoprotein 120 vaccine-induced binding antibodies to native envelope glycoprotein of human immunodeficiency virus type 1 primary isolates. National Institute of Allergy and Infectious Disease Aids Vaccine Evaluation Group.
    Gorse GJ; Patel GB; Mandava M; Berman PW; Belshe RB
    AIDS Res Hum Retroviruses; 1999 Jul; 15(10):921-30. PubMed ID: 10408729
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera.
    Wrin T; Loh TP; Vennari JC; Schuitemaker H; Nunberg JH
    J Virol; 1995 Jan; 69(1):39-48. PubMed ID: 7983734
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Resistance of previously infected chimpanzees to successive challenges with a heterologous intraclade B strain of human immunodeficiency virus type 1.
    Shibata R; Siemon C; Cho MW; Arthur LO; Nigida SM; Matthews T; Sawyer LA; Schultz A; Murthy KK; Israel Z; Javadian A; Frost P; Kennedy RC; Lane HC; Martin MA
    J Virol; 1996 Jul; 70(7):4361-9. PubMed ID: 8676459
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Induction of antibodies to the human immunodeficiency virus type 1 by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing determinant of the envelope protein.
    Zaghouani H; Anderson SA; Sperber KE; Daian C; Kennedy RC; Mayer L; Bona CA
    Proc Natl Acad Sci U S A; 1995 Jan; 92(2):631-5. PubMed ID: 7831341
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Screening of HIV-1 Env glycoproteins for the ability to raise neutralizing antibody using DNA immunization and recombinant vaccinia virus boosting.
    Richmond JF; Mustafa F; Lu S; Santoro JC; Weng J; O'Connell M; Fenyö EM; Hurwitz JL; Montefiori DC; Robinson HL
    Virology; 1997 Apr; 230(2):265-74. PubMed ID: 9143282
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Observations after human immunodeficiency virus immunization and challenge of human immunodeficiency virus seropositive and seronegative chimpanzees.
    Gibbs CJ; Peters R; Gravell M; Johnson BK; Jensen FC; Carlo DJ; Salk J
    Proc Natl Acad Sci U S A; 1991 Apr; 88(8):3348-52. PubMed ID: 2014254
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals.
    Honda M; Matsuo K; Nakasone T; Okamoto Y; Yoshizaki H; Kitamura K; Sugiura W; Watanabe K; Fukushima Y; Haga S; Katsura Y; Tasaka H; Komuro K; Yamada T; Asano T; Yamazaki A; Yamazaki S
    Proc Natl Acad Sci U S A; 1995 Nov; 92(23):10693-7. PubMed ID: 7479867
    [TBL] [Abstract][Full Text] [Related]  

  • 49. HIV-1MN recombinant gp120 vaccine serum, which fails to neutralize primary isolates of HIV-1, does not antagonize neutralization by antibodies from infected individuals.
    Wrin T; Nunberg JH
    AIDS; 1994 Nov; 8(11):1622-3. PubMed ID: 7848602
    [No Abstract]   [Full Text] [Related]  

  • 50. Infection of vaginal and colonic epithelial cells by the human immunodeficiency virus type 1 is neutralized by antibodies raised against conserved epitopes in the envelope glycoprotein gp120.
    Furuta Y; Eriksson K; Svennerholm B; Fredman P; Horal P; Jeansson S; Vahlne A; Holmgren J; Czerkinsky C
    Proc Natl Acad Sci U S A; 1994 Dec; 91(26):12559-63. PubMed ID: 7809077
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Protection of chimpanzees from high-dose heterologous HIV-1 challenge by DNA vaccination.
    Boyer JD; Ugen KE; Wang B; Agadjanyan M; Gilbert L; Bagarazzi ML; Chattergoon M; Frost P; Javadian A; Williams WV; Refaeli Y; Ciccarelli RB; McCallus D; Coney L; Weiner DB
    Nat Med; 1997 May; 3(5):526-32. PubMed ID: 9142121
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunization of rhesus macaques with a polyvalent DNA prime/protein boost human immunodeficiency virus type 1 vaccine elicits protective antibody response against simian human immunodeficiency virus of R5 phenotype.
    Pal R; Kalyanaraman VS; Nair BC; Whitney S; Keen T; Hocker L; Hudacik L; Rose N; Mboudjeka I; Shen S; Wu-Chou TH; Montefiori D; Mascola J; Markham P; Lu S
    Virology; 2006 May; 348(2):341-53. PubMed ID: 16460776
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Induction of HIVMN neutralizing antibodies in primates using a prime-boost regimen of hybrid synthetic gp120 envelope peptides.
    Haynes BF; Torres JV; Langlois AJ; Bolognesi DP; Gardner MB; Palker TJ; Scearce RM; Jones DM; Moody MA; McDanal C
    J Immunol; 1993 Aug; 151(3):1646-53. PubMed ID: 8335949
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity of a polyvalent HIV-1 candidate vaccine based on fourteen wild type gp120 proteins in golden hamsters.
    Azizi A; Anderson DE; Ghorbani M; Gee K; Diaz-Mitoma F
    BMC Immunol; 2006 Oct; 7():25. PubMed ID: 17076905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evidence for rapid selection and deletion of HIV-1 subpopulations in vivo by V3-specific neutralizing antibody: a model of humoral-associated selection.
    Nara P; Smit L; Dunlop N; Hatch W; Merges M; Waters D; Kelliher J; Krone W; Goudsmit J
    Dev Biol Stand; 1990; 72():315-41. PubMed ID: 2282990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Analysis of neutralizing and enhancing antibodies to human immunodeficiency virus type 1 primary isolates in plasma of individuals infected with env Genetic subtype B and E viruses in Thailand.
    Auewarakul P; Louisirirotchanakul S; Sutthent R; Taechowisan T; Kanoksinsombat C; Wasi C
    Viral Immunol; 1996; 9(3):175-85. PubMed ID: 8890476
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Characteristics of primary infection of a European human immunodeficiency virus type 1 clade B isolate in chimpanzees.
    Bogers WM; Koornstra WH; Dubbes RH; ten Haaft PJ; Verstrepen BE; Jhagjhoorsingh SS; Haaksma AG; Niphuis H; Laman JD; Norley S; Schuitemaker H; Goudsmit J; Hunsmann G; Heeney JL; Wigzell H
    J Gen Virol; 1998 Dec; 79 ( Pt 12)():2895-903. PubMed ID: 9880002
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Antibody and cellular immune responses in breakthrough infection subjects after HIV type 1 glycoprotein 120 vaccination.
    Locher CP; Grant RM; Collisson EA; Reyes-Terán G; Elbeik T; Kahn JO; Levy JA
    AIDS Res Hum Retroviruses; 1999 Dec; 15(18):1685-9. PubMed ID: 10606091
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Failure of a human immunodeficiency virus type 1 (HIV-1) subtype B-derived vaccine to prevent infection of chimpanzees by an HIV-1 subtype E strain.
    Girard M; Yue L; Barré-Sinoussi F; van der Ryst E; Meignier B; Muchmore E; Fultz PN
    J Virol; 1996 Nov; 70(11):8229-33. PubMed ID: 8892959
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.